Back to Search Start Over

H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy.

Authors :
Hałasa M
Wawruszak A
Przybyszewska A
Jaruga A
Guz M
Kałafut J
Stepulak A
Cybulski M
Source :
Cells [Cells] 2019 May 22; Vol. 8 (5). Date of Electronic Publication: 2019 May 22.
Publication Year :
2019

Abstract

Acetylation and deacetylation are posttranslational modifications (PTMs) which affect the regulation of chromatin structure and its remodeling. Acetylation of histone 3 at lysine placed on position 18 (H3K18Ac) plays an important role in driving progression of many types of cancer, including breast, colon, lung, hepatocellular, pancreatic, prostate, and thyroid cancer. The aim of this review is to analyze and discuss the newest findings regarding the role of H3K18Ac and acetylation of other histones in carcinogenesis. We summarize the level of H3K18Ac in different cancer cell lines and analyze its association with patients' outcomes, including overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS). Finally, we describe future perspectives of cancer therapeutic strategies based on H3K18 modifications.

Details

Language :
English
ISSN :
2073-4409
Volume :
8
Issue :
5
Database :
MEDLINE
Journal :
Cells
Publication Type :
Academic Journal
Accession number :
31121824
Full Text :
https://doi.org/10.3390/cells8050485